# Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

> **NCT04524858** · PHASE2 · TERMINATED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 1 (actual)

## Conditions studied

- Cryopyrin-Associated Periodic Syndrome

## Interventions

- **DRUG:** ATI-450

## Key facts

- **NCT ID:** NCT04524858
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-23
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-02-25
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Due to patient enrollment challenges stemming from the COVID-19 pandemic, Aclaris has decided to focus its efforts and resources on other immuno-inflammatory diseases.
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524858, "Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04524858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*